part 1: Photoshop CS6 Extended tutorial showing how to design & create a space emblem for a futuristic starship & its crew in deep space.

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

For the best part of a decade, the company was unimpeachable. But the sudden exit of chief executive Paul McKenzie underscores the new sense of chaos around the group. It’s all just so out of ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...

CSL shares have dropped significantly in 2025, reaching a seven-year low, due to restructuring and downgraded growth prospects. The company’s core business is robust, with ongoing global demand and ...

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...

SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its ...

CSL shares are significantly down due to downgraded guidance for FY 2026, attributed to lower influenza vaccination rates in the U.S. and reduced demand in China. The revised guidance cuts its revenue ...